
Clinigen shares soar after $210m Novartis cancer drug deal
pharmafile | February 13, 2019 | News story | Research and Development |Â Â Cancer, Clinigen, Novartis, Proleukin, UK, US, oncologyÂ
British company Clinigen has bought the rights to sell Novartis’ cancer drug Proleukin in the United States in a deal worth $210 million.
Clinigen, a growing speciality pharma group, already sells Proleukin outside of the US. Proleukin is used to treat metastatic kidney cancer and metastatic melanoma.
Clinigen will pay an initial sum of $120 million for the US rights alongside a further $60 million which will be differed for a year. The remaining $30 million will be paid dependent on the drug reaching certain sales milestones.
Proleukin generated $60 million in US sales last year. Clinigen believe the drug could become an integral component of cancer combination therapies.
“This highly earnings enhancing acquisition of US rights to Proleukin is significant to the whole group not just the commercial medicines division,” said chief executive Shaun Chilton.
Shares in the firm were up by nearly 15% on announcement of the news.
Louis Goss
Related Content

AI in pharma: From lab development to patient impact
In the decade to 2025, AI use in vaccine development has increased markedly but is …

Cell therapy partnership aims to bring liver disease treatment closer to US patients
Resolution Therapeutics has partnered with the Blood Centers of America (BCA) to support community-based delivery …

Scotland starts newborn screening for SMA
As part of a two-year evaluation funded by the Scottish government and Novartis, Scotland will …






